Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have earned an average recommendation of “Moderate Buy” from the twenty-three brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $625.4737.

TMO has been the subject of several recent research reports. Leerink Partners increased their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Wednesday. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective for the company in a research report on Sunday, December 7th. Finally, Barclays boosted their target price on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 10,225 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares in the company, valued at $8,085,564.90. This trade represents a 41.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $65,247,057.48. This represents a 13.07% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 149,271 shares of company stock worth $86,507,282. Company insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently bought and sold shares of TMO. Financial Management Network Inc. increased its position in shares of Thermo Fisher Scientific by 3.7% in the third quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock valued at $248,000 after buying an additional 18 shares in the last quarter. Bruce G. Allen Investments LLC increased its holdings in Thermo Fisher Scientific by 8.8% during the 3rd quarter. Bruce G. Allen Investments LLC now owns 236 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 19 shares in the last quarter. White Pine Capital LLC raised its position in Thermo Fisher Scientific by 3.2% during the third quarter. White Pine Capital LLC now owns 611 shares of the medical research company’s stock worth $296,000 after acquiring an additional 19 shares during the last quarter. Elevation Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 35.1% in the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 20 shares in the last quarter. Finally, Hopwood Financial Services Inc. grew its position in shares of Thermo Fisher Scientific by 9.1% in the third quarter. Hopwood Financial Services Inc. now owns 239 shares of the medical research company’s stock valued at $116,000 after purchasing an additional 20 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $619.14 on Monday. The company has a market capitalization of $232.62 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 4.07 and a beta of 0.91. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $628.08. The firm has a 50-day simple moving average of $581.35 and a 200-day simple moving average of $518.09. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period last year, the firm earned $5.28 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has approved a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.